Lercanidipine hydrochloride

CLINICAL USE

Calcium-channel antagonist:Mild to moderate hypertension

DOSE IN NORMAL RENAL FUNCTION

  • 10 to 20     : mg daily

    PHARMACOKINETICS

  • Molecular weight                           :648.2
  • %Protein binding                           :>98
  • %Excreted unchanged in urine     : 50 (as metabolites)
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :8–10/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Use small doses and titrate to response
  • 10 to 20     : Use small doses and titrate to response
  • <10           : Use small doses and titrate to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Anaesthetics: enhanced hypotensive effect
  • Antibacterials: avoid concomitant use with erythromycin
  • Anti-epileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone
  • Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole – avoid concomitant useAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers
  • Antivirals: concentration increased by ritonavir – avoid concomitant useCardiac glycosides: digoxin concentration increased
  • Ciclosporin: concentration of both drugs may be increased – avoid concomitant use
  • Grapefruit juice: concentration increased – avoid concomitant useTheophylline: possibly increased theophylline concentration

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    Take before food

    OTHER INFORMATION

    Causes less peripheral oedema than other calcium-channel blockersLercanidipine hydrochloride.426 LETroZoLELetrozole

    CLINICAL USE

    Treatment of advanced breast cancer

    DOSE IN NORMAL RENAL FUNCTION

    2.5 mg daily

    PHARMACOKINETICS

  • Molecular weight                           :285.3
  • %Protein binding                           :60
  • %Excreted unchanged in urine     : 6
  • Volume of distribution (L/kg)       :1.87
  • half-life – normal/ESRD (hrs)      :48/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Probably dialysed. Use with caution
  • HD                     :Dialysed. Use with caution
  • HDF/high flux   :Dialysed. Use with caution
  • CAV/VVHD      :Probably dialysed. Use with caution

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia